Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells

Journal of Experimental Medicine

Volumn 212, Issue 3, 2015, Pages 351-367

  Ortiz, Myrna L ^a   Kumar, Vinit ^b   Martner, Anna ^a,c   Mony, Sridevi ^b   Donthireddy, Laxminarasimha ^b   Condamine, Thomas ^b   Seykora, John ^d   Knight, Stella C ^e   Malietzis, George ^e,f   Lee, Gui Han ^e,f   Moorghen, Morgan ^f   Lenox, Brianna ^a,c   Luetteke, Noreen ^a   Celis, Esteban ^g   Gabrilovich, Dmitry ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b WISTAR INSTITUTE   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f ST MARK S HOSPITAL   (United Kingdom)

^g MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN B; CD33 ANTIGEN; INTERLEUKIN 17; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PHORBOL 13 ACETATE 12 MYRISTATE; 12-O-TETRADECANOYLPHORBOL-1,3-ACETATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CELL MATURATION; COLON TUMOR; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE PREDISPOSITION; HOST CELL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MOUSE; NONHUMAN; PAPILLOMA; PHENOTYPE; PRIORITY JOURNAL; SKIN CARCINOGENESIS; SKIN TUMOR; TISSUE INJURY; ANALOGS AND DERIVATIVES; ANIMAL; CELL TRANSFORMATION; COLITIS; DRUG EFFECTS; FEMALE; IMMUNOLOGY; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; CALGRANULIN B; CD4-POSITIVE T-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; CHEMOKINE CCL4; COLITIS; FEMALE; HUMANS; MICE, TRANSGENIC; MYELOID CELLS; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE;

EID: 84924662639     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20140835     Document Type: Article

References (62)

1. Arthur, J.C., E. Perez-Chanona, M. Mühlbauer, S. Tomkovich, J.M. Uronis, T.J. Fan, B.J. Campbell, T. Abujamel, B. Dogan, A.B. Rogers, et al. 2012. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 338:120-123. http://dx.doi.org/10.1126/science .1224820
2. Balkwill, F. 2009. Tumour necrosis factor and cancer. Nat. Rev. Cancer. 9:361-371. http://dx.doi.org/10.1038/nrc2628
3. Bierie, B., and H.L. Moses. 2010. Transforming growth factor beta (TGF-β) and inflammation in cancer. Cytokine Growth Factor Rev. 21:49-59. http:// dx.doi.org/10.1016/j.cytogfr.2009.11.008
4. Brandau, S., S. Trellakis, K. Bruderek, D. Schmaltz, G. Steller, M. Elian, H. Suttmann, M. Schenck, J. Welling, P. Zabel, and S. Lang. 2011. Myeloidderived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J. Leukoc. Biol. 89:311-317. http://dx.doi.org/10.1189/jlb.0310162
5. Bromley, S.K., T.R. Mempel, and A.D. Luster. 2008. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat. Immunol. 9: 970-980. http://dx.doi.org/10.1038/ni.f.213
6. + T cell-dendritic cell interaction. Nature. 440:890-895. http://dx.doi.org/10.1038/nature04651
7. Chen, X., E.A. Eksioglu, J. Zhou, L. Zhang, J. Djeu, N. Fortenbery, P. Epling-Burnette, S. Van Bijnen, H. Dolstra, J. Cannon, et al. 2013. Induction of myelodysplasia by myeloid-derived suppressor cells. J. Clin. Invest. 123:4595-4611. http://dx.doi.org/10.1172/JCI67580
8. Cheng, P., C.A. Corzo, N. Luetteke, B. Yu, S. Nagaraj, M.M. Bui, M. Ortiz, W. Nacken, C. Sorg, T. Vogl, et al. 2008. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205: 2235-2249. http://dx.doi.org/10.1084/jem.20080132
9. Cho, K.A., J.Y. Kim, S.Y. Woo, H.J. Park, K.H. Lee, and C.U. Pae. 2012. Interleukin- 17 and interleukin-22 induced proinflammatory cytokine production in keratinocytes via inhibitor of nuclear factor κB kinase-α expression. Ann. Dermatol. 24:398-405. http://dx.doi.org/10.5021/ad.2012.24.4.398
10. Coussens, L.M., L. Zitvogel, and A.K. Palucka. 2013. Neutralizing tumorpromoting chronic inflammation: a magic bullet? Science. 339:286-291. http://dx.doi.org/10.1126/science.1232227
11. Cuenca, A.G., M.J. Delano, K.M. Kelly-Scumpia, C. Moreno, P.O. Scumpia, D.M. Laface, P.G. Heyworth, P.A. Efron, and L.L. Moldawer. 2011. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol. Med. 17:281-292. http://dx.doi.org/10.2119/molmed.2010.00178
12. Dalgleish, A.G., and K. O'Byrne. 2006. Inflammation and cancer: the role of the immune response and angiogenesis. Cancer Treat. Res. 130:1-38. http://dx.doi.org/10.1007/0-387-26283-0_1
13. + T cells. J. Exp. Med. 197:1017-1028. http://dx.doi.org/10.1084/ jem.20021047
14. + T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res. 65:2018-2025. http://dx.doi.org/10.1158/0008-5472.CAN-04-3444
15. DeNardo, D.G., P. Andreu, and L.M. Coussens. 2010. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev. 29:309-316. http://dx.doi.org/10.1007/ s10555-010-9223-6
16. Dyer, R.K., M.A. Weinstock, T.S. Cohen, A.E. Rizzo, and S.F. Bingham; VATTC Trial Group. 2012. Predictors of basal cell carcinoma in highrisk patients in the VATTC (VA Topical Tretinoin Chemoprevention) trial. J. Invest. Dermatol. 132:2544-2551. http://dx.doi.org/10.1038/ jid.2012.227
17. Dyson, J.K., and M.D. Rutter. 2012. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J. Gastroenterol. 18:3839-3848. http://dx.doi.org/10.3748/wjg.v18.i29.3839
18. Ehrchen, J.M., C. Sunderkötter, D. Foell, T. Vogl, and J. Roth. 2009. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J. Leukoc. Biol. 86:557-566. http://dx.doi.org/10.1189/jlb.1008647
19. + monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. Am. J. Respir. Crit. Care Med. 186:1025- 1036. http://dx.doi.org/10.1164/rccm.201204-0636OC
20. Fridlender, Z.G., J. Sun, S. Kim, V. Kapoor, G. Cheng, L. Ling, G.S. Worthen, and S.M. Albelda. 2009. Polarization of tumor-associated neutrophil phenotype by TGF-β: "N1" versus "N2" TAN. Cancer Cell. 16:183-194. http://dx.doi.org/10.1016/j.ccr.2009.06.017
21. Fujita, H. 2013. The role of IL-22 and Th22 cells in human skin diseases. J. Dermatol. Sci. 72:3-8. http://dx.doi.org/10.1016/j.jdermsci.2013.04.028
22. Gabrilovich, D.I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9:162-174. http://dx.doi.org/10.1038/nri2506
23. Gabrilovich, D.I., G.M. Woods, S. Patterson, J.J. Harvey, and S.C. Knight. 1994. Retrovirus-induced immunosuppression via blocking of dendritic cell migration and down-regulation of adhesion molecules. Immunology. 82:82-87.
24. Gabrilovich, D.I., S. Ostrand-Rosenberg, and V. Bronte. 2012. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12:253-268. http://dx.doi.org/10.1038/nri3175
25. Gasche, C., C.L. Chang, J. Rhees, A. Goel, and C.R. Boland. 2001. Oxidative stress increases frameshift mutations in human colorectal cancer cells. Cancer Res. 61:7444-7448.
26. Gebhardt, C., A. Riehl, M. Durchdewald, J. Németh, G. Fürstenberger, K. Müller-Decker, A. Enk, B. Arnold, A. Bierhaus, P.P. Nawroth, et al. 2008. RAGE signaling sustains inflammation and promotes tumor development. J. Exp. Med. 205:275-285. http://dx.doi.org/10.1084/jem.20070679
27. + T cells to different stages of chemically induced skin cancer. J. Exp. Med. 198:747-755. http://dx.doi .org/10.1084/jem.20021282
28. Güngör, N., R.W. Godschalk, D.M. Pachen, F.J. Van Schooten, and A.M. Knaapen. 2007. Activated neutrophils inhibit nucleotide excision repair in human pulmonary epithelial cells: role of myeloperoxidase. FASEB J. 21:2359-2367. http://dx.doi.org/10.1096/fj.07-8163com
29. Hagemann, T., and F. Balkwill. 2005. MIFed about cancer? Gastroenterology. 129:1785-1787. http://dx.doi.org/10.1053/j.gastro.2005.09.039
30. He, D., H. Li, N. Yusuf, C.A. Elmets, J. Li, J.D. Mountz, and H. Xu. 2010. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J. Immunol. 184:2281-2288. http://dx.doi.org/10.4049/jimmunol .0902574
31. Heidenreich, R., M. Röcken, and K. Ghoreschi. 2009. Angiogenesis drives psoriasis pathogenesis. Int. J. Exp. Pathol. 90:232-248. http://dx.doi .org/10.1111/j.1365-2613.2009.00669.x
32. + dermal dendritic cells cross-present keratinocytederived antigens irrespective of the presence of Langerhans cells. J. Exp. Med. 207:189-206. http://dx.doi.org/10.1084/jem.20091964
33. Hofseth, L.J., S. Saito, S.P. Hussain, M.G. Espey, K.M. Miranda, Y. Araki, C. Jhappan, Y. Higashimoto, P. He, S.P. Linke, et al. 2003. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc. Natl. Acad. Sci. USA. 100:143-148. http://dx.doi.org/10.1073/pnas.0237083100
34. Huang, Y., L. Lin, A. Shanker, A. Malhotra, L. Yang, M.M. Dikov, and D.P. Carbone. 2011. Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth. Cancer Res. 71:6122-6131. http://dx.doi.org/ 10.1158/0008-5472.CAN-10-4366
35. Humble, M.C., C.S. Trempus, J.W. Spalding, R.E. Cannon, and R.W. Tennant. 2005. Biological, cellular, and molecular characteristics of an inducible transgenic skin tumor model: a review. Oncogene. 24:8217-8228. http:// dx.doi.org/10.1038/sj.onc.1209000
36. Ichikawa, M., R. Williams, L. Wang, T. Vogl, and G. Srikrishna. 2011. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol. Cancer Res. 9:133-148. http://dx.doi.org/10.1158/1541-7786.MCR-10-0394
37. - cells show distinct function in mice with chronic inflammation or tumor burden. BMC Immunol. 13:69. http://dx.doi .org/10.1186/1471-2172-13-69
38. Kim, S.F., D.A. Huri, and S.H. Snyder. 2005. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science. 310:1966-1970. http://dx.doi.org/10.1126/science.1119407
39. Koebel, C.M., W. Vermi, J.B. Swann, N. Zerafa, S.J. Rodig, L.J. Old, M.J. Smyth, and R.D. Schreiber. 2007. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 450:903-907. http://dx.doi .org/10.1038/nature06309
40. Le'Negrate, G., P. Rostagno, P. Auberger, B. Rossi, and P. Hofman. 2003. Downregulation of caspases and Fas ligand expression, and increased lifespan of neutrophils after transmigration across intestinal epithelium. Cell Death Differ. 10:153-162. http://dx.doi.org/10.1038/sj.cdd.4401110
41. Leder, A., A. Kuo, R.D. Cardiff, E. Sinn, and P. Leder. 1990. v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. Proc. Natl. Acad. Sci. USA. 87:9178- 9182. http://dx.doi.org/10.1073/pnas.87.23.9178
42. Manitz, M.P., B. Horst, S. Seeliger, A. Strey, B.V. Skryabin, M. Gunzer, W. Frings, F. Schönlau, J. Roth, C. Sorg, and W. Nacken. 2003. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol. Cell. Biol. 23:1034-1043. http://dx.doi.org/10.1128/MCB.23.3.1034-1043.2003
43. Markowitz, J., and W.E. Carson III. 2013. Review of S100A9 biology and its role in cancer. Biochim. Biophys. Acta. 1835:100-109. http://dx.doi .org/10.1016/j.bbcan.2012.10.003
44. Marnett, L.J. 2000. Oxyradicals and DNA damage. Carcinogenesis. 21:361- 370. http://dx.doi.org/10.1093/carcin/21.3.361
45. McNeill, E., and N. Hogg. 2014. S100A9 has a protective role in inflammationinduced skin carcinogenesis. Int. J. Cancer. 135:798-808. http://dx.doi .org/10.1002/ijc.28725
46. Nagaraj, S., J.I. Youn, and D.I. Gabrilovich. 2013. Reciprocal relationship between myeloid-derived suppressor cells and T cells. J. Immunol. 191:17-23. http://dx.doi.org/10.4049/jimmunol.1300654
47. + Th17 cells and IL-13 signaling attenuates Th17 cytokine production. J. Immunol. 182:5317-5321. http://dx.doi .org/10.4049/jimmunol.0803868
48. Ortiz, M.L., L. Lu, I. Ramachandran, and D.I. Gabrilovich. 2014. Myeloidderived suppressor cells in the development of lung cancer. Cancer Immunol. Res. 2:50-58. http://dx.doi.org/10.1158/2326-6066 .CIR-13-0129
49. Peranzoni, E., S. Zilio, I. Marigo, L. Dolcetti, P. Zanovello, S. Mandruzzato, and V. Bronte. 2010. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22:238-244. http://dx.doi.org/ 10.1016/j.coi.2010.01.021
50. Schlecker, E., A. Stojanovic, C. Eisen, C. Quack, C.S. Falk, V. Umansky, and A. Cerwenka. 2012. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J. Immunol. 189:5602-5611. http://dx.doi.org/ 10.4049/jimmunol.1201018
51. Schmid, M.C., and J.A. Varner. 2012. Myeloid cells in tumor inflammation. Vasc. Cell. 4:14. http://dx.doi.org/10.1186/2045-824X-4-14
52. Shimizu, K., P. Libby, V.Z. Rocha, E.J. Folco, R. Shubiki, N. Grabie, S. Jang, A.H. Lichtman, A. Shimizu, N. Hogg, et al. 2011. Loss of myeloid related protein-8/14 exacerbates cardiac allograft rejection. Circulation. 124:2920-2932. http://dx.doi.org/10.1161/CIRCULATIONAHA .110.009910
53. Sica, A., and V. Bronte. 2007. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117:1155-1166. http://dx.doi.org/10.1172/JCI31422
54. Sinha, P., C. Okoro, D. Foell, H.H. Freeze, S. Ostrand-Rosenberg, and G. Srikrishna. 2008. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 181:4666-4675. http://dx.doi.org/10.4049/jimmunol.181.7.4666
55. Sorenson, B.S., A. Khammanivong, B.D. Guenther, K.F. Ross, and M.C. Herzberg. 2012. IL-1 receptor regulates S100A8/A9-dependent keratinocyte resistance to bacterial invasion. Mucosal Immunol. 5:66-75. http://dx.doi .org/10.1038/mi.2011.48
56. Srivastava, M.K., Å. Andersson, L. Zhu, M. Harris-White, J.M. Lee, S. Dubinett, and S. Sharma. 2012. Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy. 4:291-304. http://dx.doi .org/10.2217/imt.11.178
57. Talmadge, J.E., and D.I. Gabrilovich. 2013. History of myeloid-derived suppressor cells. Nat. Rev. Cancer. 13:739-752. http://dx.doi.org/10.1038/nrc3581
58. Tepper, R.I., D.A. Levinson, B.Z. Stanger, J. Campos-Torres, A.K. Abbas, and P. Leder. 1990. IL-4 induces allergic-like inflammatory disease and alters T cell development in transgenic mice. Cell. 62:457-467. http://dx.doi .org/10.1016/0092-8674(90)90011-3
59. Wang, L., T. Yi, W. Zhang, D.M. Pardoll, and H. Yu. 2010. IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res. 70:10112- 10120. http://dx.doi.org/10.1158/0008-5472.CAN-10-0775
60. Xiao, M., C. Wang, J. Zhang, Z. Li, X. Zhao, and Z. Qin. 2009. IFNγ promotes papilloma development by up-regulating Th17-associated inflammation. Cancer Res. 69:2010-2017. http://dx.doi.org/10.1158/0008-5472 .CAN-08-3479
61. Youn, J.-I., M. Collazo, I.N. Shalova, S.K. Biswas, and D.I. Gabrilovich. 2012. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J. Leukoc. Biol. 91:167-181. http://dx .doi.org/10.1189/jlb.0311177
62. Zhao, F., B. Hoechst, A. Duffy, J. Gamrekelashvili, S. Fioravanti, M.P. Manns, T.F. Greten, and F. Korangy. 2012. S100A9 a new marker for monocytic human myeloid-derived suppressor cells. Immunology. 136:176-183. http://dx.doi.org/10.1111/j.1365-2567.2012.03566.x